Further, tropifexor was shown to regulate distinct sets of genes in experimental NASH as compared to other FXR agonists, particularly genes involved in fibrosis, inflammation, and oxidative stress (Hernandez et al., 2019). The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.